CN115697298A - 脂质纳米颗粒 - Google Patents

脂质纳米颗粒 Download PDF

Info

Publication number
CN115697298A
CN115697298A CN202180010449.4A CN202180010449A CN115697298A CN 115697298 A CN115697298 A CN 115697298A CN 202180010449 A CN202180010449 A CN 202180010449A CN 115697298 A CN115697298 A CN 115697298A
Authority
CN
China
Prior art keywords
lipid
mole
mrna
lipids
peg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180010449.4A
Other languages
English (en)
Chinese (zh)
Inventor
S·德科克
S·贝维尔斯
R·M·希弗勒斯
S·A·A·库伊曼斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ezer Arne Immunotherapy Co ltd
Universite Libre de Bruxelles ULB
Original Assignee
Ezer Arne Immunotherapy Co ltd
Universite Libre de Bruxelles ULB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ezer Arne Immunotherapy Co ltd, Universite Libre de Bruxelles ULB filed Critical Ezer Arne Immunotherapy Co ltd
Publication of CN115697298A publication Critical patent/CN115697298A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202180010449.4A 2020-01-21 2021-01-21 脂质纳米颗粒 Pending CN115697298A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP20152995.5 2020-01-21
EP20152995 2020-01-21
EP20152938 2020-01-21
EP20152938.5 2020-01-21
EP20179434.4 2020-06-11
EP20179434 2020-06-11
PCT/EP2021/051290 WO2021148511A1 (en) 2020-01-21 2021-01-21 Lipid nanoparticles

Publications (1)

Publication Number Publication Date
CN115697298A true CN115697298A (zh) 2023-02-03

Family

ID=74215945

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180010449.4A Pending CN115697298A (zh) 2020-01-21 2021-01-21 脂质纳米颗粒

Country Status (12)

Country Link
US (1) US20230067722A1 (https=)
EP (1) EP4093373A1 (https=)
JP (1) JP2023517275A (https=)
KR (1) KR20230002300A (https=)
CN (1) CN115697298A (https=)
AU (1) AU2021211894A1 (https=)
BR (1) BR112022013837A2 (https=)
CA (1) CA3168696A1 (https=)
IL (1) IL294624A (https=)
MX (1) MX2022009018A (https=)
TW (1) TW202139975A (https=)
WO (1) WO2021148511A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115887674A (zh) * 2022-04-29 2023-04-04 北京剂泰医药科技有限公司 脂质纳米颗粒
CN115998714A (zh) * 2023-03-20 2023-04-25 威瑞生物科技(昆明)有限责任公司 一种脂质纳米颗粒、递送系统及递送系统的制备方法
CN117159492A (zh) * 2023-07-27 2023-12-05 广州制高点医药科技有限公司 一种含有唾液酸脂质衍生物的脂质纳米颗粒及其应用

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020182993A1 (en) * 2019-03-13 2020-09-17 Etherna Immunotherapies Nv Mrna vaccine
WO2022115645A1 (en) 2020-11-25 2022-06-02 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids, and related methods of use
EP4346901A4 (en) * 2021-06-01 2025-04-23 The University of British Columbia MRNA DELIVERY USING LIPID NANOPARTICLES
CA3238764A1 (en) * 2021-11-23 2023-06-01 Siddharth Patel A bacteria-derived lipid composition and use thereof
CN114716355B (zh) * 2022-04-02 2023-09-05 华南理工大学 一种脂质化合物、包含其的组合物及应用
CA3256897A1 (en) 2022-05-25 2023-11-30 Akagera Medicines, Inc. Lipid nanoparticles for the administration of nucleic acids and their methods of use
CN115414476B (zh) * 2022-08-15 2023-07-14 珠海暨创硒源纳米科技有限公司 一种改性氧化镁、含镁纳米颗粒水溶液及其制备方法与在制备佐剂中的应用
WO2024064206A1 (en) * 2022-09-20 2024-03-28 Emory University Lipid nanoparticles comprising nucleic acids encoding therapeutic genes and uses in medical methods
CN116763756A (zh) * 2022-10-11 2023-09-19 中国科学院化学研究所 一种脂质纳米颗粒及其制备方法和应用
JP7813825B2 (ja) * 2023-02-07 2026-02-13 株式会社微生物化学研究所 ワクチン
EP4442256A1 (en) 2023-04-04 2024-10-09 Københavns Universitet Lipid nanoparticle compositions
AU2024279278A1 (en) 2023-05-31 2025-12-18 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
CN120359024A (zh) 2023-10-12 2025-07-22 科百博生物股份有限公司 脂质纳米颗粒

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102216462A (zh) * 2008-11-17 2011-10-12 安龙制药公司 用于核酸递送系统的支化阳离子脂质
JP2014523870A (ja) * 2011-06-08 2014-09-18 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド 切断可能な脂質
WO2016118725A1 (en) * 2015-01-23 2016-07-28 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
WO2017218704A1 (en) * 2016-06-14 2017-12-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
US20170367988A1 (en) * 2016-05-09 2017-12-28 Astrazeneca Ab Lipid nanoparticles comprising lipophilic anti-inflammatory agents and methods of use thereof
CN109563511A (zh) * 2016-06-30 2019-04-02 阿布特斯生物制药公司 用于递送信使rna的组合物和方法
WO2019131580A1 (ja) * 2017-12-27 2019-07-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 カチオン性脂質
WO2019141814A1 (en) * 2018-01-18 2019-07-25 Etherna Immunotherapies Nv Lipid nanoparticles

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3243504A1 (en) * 2009-01-29 2017-11-15 Arbutus Biopharma Corporation Improved lipid formulation
KR101766408B1 (ko) * 2009-06-10 2017-08-10 알닐람 파마슈티칼스 인코포레이티드 향상된 지질 조성물
AU2014340149B2 (en) * 2013-10-22 2020-12-24 Shire Human Genetic Therapies, Inc. CNS delivery of mRNA and uses thereof
HUE058792T2 (hu) 2013-11-12 2022-09-28 Univ Brussel Vrije RNS-transzkripciós vektor és felhasználása
PL3386484T3 (pl) * 2015-12-10 2022-07-25 Modernatx, Inc. Kompozycje i sposoby dostarczania środków terapeutycznych
WO2018175783A1 (en) * 2017-03-22 2018-09-27 Modernatx, Inc. Rna bacterial vaccines

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102216462A (zh) * 2008-11-17 2011-10-12 安龙制药公司 用于核酸递送系统的支化阳离子脂质
JP2014523870A (ja) * 2011-06-08 2014-09-18 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド 切断可能な脂質
WO2016118725A1 (en) * 2015-01-23 2016-07-28 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
US20170367988A1 (en) * 2016-05-09 2017-12-28 Astrazeneca Ab Lipid nanoparticles comprising lipophilic anti-inflammatory agents and methods of use thereof
WO2017218704A1 (en) * 2016-06-14 2017-12-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
CN109563511A (zh) * 2016-06-30 2019-04-02 阿布特斯生物制药公司 用于递送信使rna的组合物和方法
WO2019131580A1 (ja) * 2017-12-27 2019-07-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 カチオン性脂質
WO2019141814A1 (en) * 2018-01-18 2019-07-25 Etherna Immunotherapies Nv Lipid nanoparticles

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LISA MUNAKATA，等: "Lipid nanoparticles of Type-A CpG D35 suppress tumor growth by changing tumor immune-microenvironment and activate CD8 T cells in mice", JOURNAL OF CONTROLLED RELEASE, vol. 313, 16 October 2019 (2019-10-16), pages 106 - 119, XP085925532, DOI: 10.1016/j.jconrel.2019.09.011 *
YANJIE BAO，等: "Effect of PEGylation on biodisrtibution and gene silencing of siRNA/lipid nanoparticle complex", PHARMACEUTICAL RESEARCH, vol. 30, 15 September 2012 (2012-09-15), pages 342 - 351 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115887674A (zh) * 2022-04-29 2023-04-04 北京剂泰医药科技有限公司 脂质纳米颗粒
CN115887674B (zh) * 2022-04-29 2023-08-25 北京剂泰医药科技有限公司 脂质纳米颗粒
CN115998714A (zh) * 2023-03-20 2023-04-25 威瑞生物科技(昆明)有限责任公司 一种脂质纳米颗粒、递送系统及递送系统的制备方法
CN117159492A (zh) * 2023-07-27 2023-12-05 广州制高点医药科技有限公司 一种含有唾液酸脂质衍生物的脂质纳米颗粒及其应用

Also Published As

Publication number Publication date
EP4093373A1 (en) 2022-11-30
BR112022013837A2 (pt) 2022-09-13
MX2022009018A (es) 2022-08-11
AU2021211894A1 (en) 2022-09-01
US20230067722A1 (en) 2023-03-02
TW202139975A (zh) 2021-11-01
WO2021148511A1 (en) 2021-07-29
JP2023517275A (ja) 2023-04-25
CA3168696A1 (en) 2021-07-29
KR20230002300A (ko) 2023-01-05
IL294624A (en) 2022-09-01

Similar Documents

Publication Publication Date Title
CN115697298A (zh) 脂质纳米颗粒
US20240261381A1 (en) Lipid nanoparticles
JP7096282B2 (ja) 免疫療法のためのｒｎａ製剤
JP2021511376A (ja) 脂質ナノ粒子
JP7740988B2 (ja) 前立腺癌のための治療用ｒｎａ
JP2023520506A (ja) Ｓａｒｓ－ｃｏｖ－２に対する多層ｒｎａナノ粒子ワクチン
RU2837542C1 (ru) Липидные наночастицы
TWI920113B (zh) 脂質奈米粒子
HK40087510A (zh) 脂质纳米颗粒
TW202304505A (zh) 脂質奈米粒子
HK40094060A (zh) 脂质纳米颗粒
WO2026047192A1 (en) Ionizable lipids
HK40113162A (zh) 多核苷酸组合物及其用途
HK40127068A (zh) 脂质纳米颗粒
CN118647397A (zh) 多核苷酸组合物及其用途
JP2014114267A (ja) 脂質膜構造体に対して肝臓血管内皮細胞への移行能を付与および／または増強するペプチド、肝臓血管内皮細胞への移行能を有するまたは肝臓血管内皮細胞への移行能が増強された脂質膜構造体、ならびに脂質膜構造体に対して肝臓血管内皮細胞への移行能を付与および／または増強する剤
HK40041286B (zh) 脂质纳米颗粒
HK40041286A (en) Lipid nanoparticles

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40087510

Country of ref document: HK